top of page

Artifical Intelligence
Machine Learning

We are an multi-disciplinary team of computational and experimental scientists focused on shortening the traditional time-to-development for antiviral drugs by integrating artificial intelligence (AI) and machine learning (ML), high-performance computing (HPC), and high-throughput experimental screening into every step of the drug design process to identify novel viral targets and develop safe and effective antiviral therapeutics.

Felice C. Lightstone, Ph.D.

Principal Investigator

Don Francis

Lawrence Livermore National Laboratory

Group Leader

Associate Program Lead of Medical Countermeasures

My research uses cutting-edge, multi-scale, in silico simulations to tackle problems in biology. A wide range of computational biology and machine learning methods that employ LLNL’s high-performance computing resources are used to accelerate the design and development of new therapies.
  • Facebook
  • Twitter
  • LinkedIn

Adam Godzik, Ph.D.

University of California, Riverside

Professor of Biomedical Sciences

My research combines insights from physics and biology to answer the questions about the relation between the protein sequence and it structure and function.  

  • Facebook
  • Twitter
  • LinkedIn

Sandia National Laboratories

Staff Scientist

Oscar Negrete, Ph.D.

Tess Brown

Sandia National Laboratories

Staff Scientist

My research uses a broad spectrum of cellular, molecular biology, functional genomics, and nanotechnologies to assist in the formulation of new countermeasures and diagnostics for emerging infectious disease pathogens. I will bring his experience in Nipah virus entry research.

  • Facebook
  • Twitter
  • LinkedIn

Maurizio Pellecchia, Ph.D.

University of California, Riverside

Professor of Biomedical Sciences

Director, Center for Molecular and Translational Medicine

A central theme of my laboratory is the development of novel methodologies to tackle protein-protein interactions (PPIs) as targets for drug discovery, and to further advance our most promising agents into potential therapeutics.

  • Facebook
  • Twitter
  • LinkedIn

Sandia National Laboratories

Staff Scientist

Rommie Amaro, Ph.D.

University of California, San Diego

Professor and Endowed Chair

Department of Chemistry and Biochemistry

My research is broadly concerned with the development and application of state-of-the-art computational methods to address outstanding questions in drug discovery and molecular-level biophysics.

  • Facebook
  • Twitter
  • LinkedIn

Jonathan Allen, Ph.D.

Lawrence Livermore National Laboratory

Bioinformaticist

My research focuses on using machine learning and artificial intelligence to build models of the drugs' effectiveness and predict draggability.

  • Facebook
  • Twitter
  • LinkedIn
Jonathan-Allen-LLNL.jpeg
edlau2.jpg

Edmond Lau, Ph.D.

Lawrence Livermore National Laboratory

Computational Chemist

My research applies molecular dynamics, quantum mechanical calculations, and molecular docking to study biological systems, including small molecule inhibitor and antibody designs to inhibit SARS-CoV-2.

  • Facebook
  • Twitter
  • LinkedIn

Brooke Harmon, Ph.D.

Sandia National Laboratories

Staff Scientist

My research is focused on rapidly identifying and engineering novel antibody-based therapeutics with enhanced immuno-protective characteristics and efficient tissue penetration to combat encephalitic alphaviruses and SARS-CoV-2

  • Facebook
  • Twitter
  • LinkedIn
Brooke Harmon image.JPG
McLoughlin head shot.jpg

Kevin McLoughlin, Ph.D.

Lawrence Livermore National Laboratory

Computational Biologist

My research focuses on machine learning methods applied to computational drug discovery and drug safety with a strong background in experimental design and experimental data analysis.

  • Facebook
  • Twitter
  • LinkedIn

Hyojin Kim, Ph.D.

Lawrence Livermore National Laboratory

Computer Scientist

My research interests are broad areas of computer vision, image understanding and machine learning, including application to drug discovery

  • Facebook
  • Twitter
  • LinkedIn
HyojinKim-LLNL.jpg
U19_Bio_XiaohuaZhang_Photo.jpg

Xiaohua Zhang, Ph.D.

My research interests include: (i) drug discovery and high-throughput drug screening C++ toolkit development; (ii) fragment- and structure-based drug design; (iii) high performance computing applied to computational chemistry; (iv) algorithm derivation and program engineering for molecular simulation.

  • Facebook
  • Twitter
  • LinkedIn

Lawrence Livermore National Laboratory

Computational Chemist

Brian Bennion, Ph.D.

Lawrence Livermore National Laboratory

Computational Chemist

My research interests are in computational prediction and optimization of small molecules for the discovery of molecular therapeutics.

  • Facebook
  • Twitter
  • LinkedIn
BennionHeadShot.jpeg
Zemla_HeadShot.jpeg

Adam Zemla, Ph.D.

Lawrence Livermore National Laboratory

Computer Scientist

My research interests lie in developing new computational methods and numerical evaluation schemes to help detect and extract biologically meaningful inferences from complex biological datasets. 

  • Facebook
  • Twitter
  • LinkedIn

Dina R. Weilhammer, Ph.D.

Lawrence Livermore National Laboratory

Biomedical Scientist

My research focuses on innate and adaptive immune responses to viruses of biodefense and public health concern, including SARS-CoV-2. I have developed in vitro and in vivo infection models, including select agent pathogens under A/BSL3 Tier one Select Agent containment.

  • Facebook
  • Twitter
  • LinkedIn
Weilhammer head shot.jpg

Nicole Collette, Ph.D.

Lawrence Livermore National Laboratory

Biomedical Scientist

Director, Animal Care Facility

With over 20 years of hands-on, in vivo mouse experimentation. my research has been in a wide variety of areas, including forensics, toxicology, infectious disease diagnostics, pathogen evolution, and therapeutic development.

  • Facebook
  • Twitter
  • LinkedIn
collette.jpg
bottom of page